Designing and developing suppository formulations for anti-HIV drug delivery

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 History of the Suppository Form. Aiache JM, Renoux R, Fistre D (Eds). J.R. Prous Publishers, Barcelona, Spain (1984).
  Google Scholar
• 2 Shah SM, Sultan AH, Thakar R. The history and evolution of pessaries for pelvic organ prolapse. Int. Urogynecol. J. Pelvic Floor Dysfunct. 17(2), 170–175 (2006).
  MedlineGoogle Scholar
• 3 FDA. U.S. Food and Drug Administration: Rectal Drugs. 2017(03–01). www.fda.gov.
  Google Scholar
• 4 FDA. U.S. Food and Drug Administration: Vaginal Drugs. 2017(4/20). www.fda.gov.
  Google Scholar
• 5 Jannin V, Lemagnen G, Gueroult P, Larrouture D, Tuleu C. Rectal route in the 21st Century to treat children. Adv. Drug. Deliv. Re.v 73, 34–49 (2014). •• A comprehensive review of suppositories for pediatric administration and the role of suppositories in the world market.
  Medline CASGoogle Scholar
• 6 Pharmacopoeia E. European Directorate for the Quality of Medicines and Healthcare. Rectal Preparations EP 01/2008:1145 (2011).
  Google Scholar
• 7 Pharmacopoeia US. The U.S. Pharmacopoeia. Nomenclature Guidlines <1121> 36 (2016).
  Google Scholar
• 8 Pharmacopoeia J. The Japanese Pharmacopoeia: 17th Edition. Monogrpahs for Preparations 18–19 (2016).
  Google Scholar
• 9 Ham AS, Ugaonkar SR, Shi L et al. Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection. J. Pharm. Sci. 101(4), 1423–1435 (2012).
  Medline CASGoogle Scholar
• 10 Dezzutti CS, Rohan LC, Wang L et al. Reformulated tenofovir gel for use as a dual compartment microbicide. J. Antimicrob. Chemother. 67(9), 2139–2142 (2012).
  Medline CASGoogle Scholar
• 11 Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS ONE 5(2), e9310 (2010).
  MedlineGoogle Scholar
• 12 Akil A, Parniak M, Dezzutti C et al. Development and characterization of a vaginal film containing dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for prevention of HIV-1 sexual transmission. Drug Deliv. Transl. Res. 1(3), 209–222 (2011).
  Medline CASGoogle Scholar
• 13 Gupta KM, Pearce SM, Poursaid AE et al. Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J. Pharm. Sci. 97(10), 4228–4239 (2008).
  Medline CASGoogle Scholar
• 14 Ham AS, Rohan LC, Boczar A, Yang L, Buckheit K, Buckheit RW Jr. Vaginal film drug delivery of the pyrimidinedione IQP-0528 for the prevention of HIV infection. Pharm. Res. (2012).
  MedlineGoogle Scholar
• 15 Ham AS, Nugent ST, Peters JJ et al. The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention. Antiviral. Res. 120, 153–164 (2015).
  Medline CASGoogle Scholar
• 16 Dezzutti CS, Yandura S, Wang L et al. Pharmacodynamic activity of dapivirine and maraviroc single entity and combination topical gels for HIV-1 prevention. Pharm. Res. 32(11), 3768–3781 (2015).
  Medline CASGoogle Scholar
• 17 Das Neves J, Martins JP, Sarmento B. Will dapivirine redeem the promises of anti-HIV microbicides? Overview of product design and clinical testing. Adv. Drug. Deliv. Rev. 103, 20–32 (2016).
  Medline CASGoogle Scholar
• 18 Naicker N, Naidoo A, Werner L et al. Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials. Antivir. Ther. (2016).
  MedlineGoogle Scholar
• 19 Pereira LE, Mesquita PM, Ham A et al. Pharmacokinetic and pharmacodynamic evaluation following vaginal application of IQB3002, a dual-chamber microbicide gel containing the nonnucleoside reverse transcriptase inhibitor IQP-0528 in Rhesus macaques. Antimicrob. Agents. Chemother. 60(3), 1393–1400 (2015).
  MedlineGoogle Scholar
• 20 Marrazzo JM, Ramjee G, Richardson BA et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 372(6), 509–518 (2015).
  MedlineGoogle Scholar
• 21 Rees H, Delany-Moretlwe S, Baron D et al. FACTS 001 Phase III trial of pericoital tenofovir 1% gel for HIV prevention in women. CROI (2015). • A report on the clinical trial of a vaginally administered microbicide in African women. The results illustrate the need to consider user acceptability in HIV prevention design.
  Google Scholar
• 22 Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329(5996), 1168–1174 (2010).
  Medline CASGoogle Scholar
• 23 Van Der Straten A, Stadler J, Montgomery E et al. Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS ONE 9(2), e89118 (2014).
  MedlineGoogle Scholar
• 24 Zhang W, Hu M, Shi Y et al. Vaginal microbicide film combinations of two reverse transcriptase inhibitors, EFdA and CSIC, for the prevention of HIV-1 sexual transmission. Pharm. Res. 32(9), 2960–2972 (2015).
  Medline CASGoogle Scholar
• 25 Grammen C, Van Den Mooter G, Appeltans B et al. Development and characterization of a solid dispersion film for the vaginal application of the anti-HIV microbicide UAMC01398. Int. J. Pharm. 475(1–2), 238–244 (2014).
  Medline CASGoogle Scholar
• 26 Peitzmeier SM, Tomko C, Wingo E et al. Acceptability of microbicidal vaginal rings and oral pre-exposure prophylaxis for HIV prevention among female sex workers in a high-prevalence US city. AIDS Care 1–5 (2017).
  MedlineGoogle Scholar
• 27 Clark JT, Clark MR, Shelke NB et al. Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy. PLoS ONE 9(3), e88509 (2014).
  MedlineGoogle Scholar
• 28 Baeten JM, Palanee-Phillips T, Brown ER et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N. Engl. J. Med. 375(22), 2121–2132 (2016).
  Medline CASGoogle Scholar
• 29 Pines HA, Gorbach PM, Weiss RE et al. Acceptability of potential rectal microbicide delivery systems for HIV prevention: a randomized crossover trial. AIDS Behav. 17(3), 1002–1015 (2013).
  MedlineGoogle Scholar
• 30 Newman PA, Cameron MP, Roungprakhon S, Tepjan S, Scarpa R. Acceptability and preferences for hypothetical rectal microbicides among a community sample of young men who have sex with men and transgender women in Thailand: a discrete choice experiment. AIDS Behav. 20(11), 2588–2601 (2016).
  MedlineGoogle Scholar
• 31 Vargas SE, Fava JL, Severy L et al. Psychometric properties and validity of a multi-dimensional risk perception scale developed in the context of a microbicide acceptability study. Arch. Sex. Behav. 45(2), 415–428 (2016).
  MedlineGoogle Scholar
• 32 Weld ED, Hiruy H, Guthrie KM et al. A comparative pre-Phase I study of the impact of gel vehicle volume on distal colon distribution, user experience, and acceptability. AIDS. Res. Hum. Retroviruses (33(5), 440–447 (2016).
  MedlineGoogle Scholar
• 33 Morrow KM, Underhill K, Van Den Berg JJ, Vargas S, Rosen RK, Katz DF. User-identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides. Arch. Sex. Behav. 43(7), 1459–1467 (2014).
  MedlineGoogle Scholar
• 34 Morrow K, Ruiz M. Assessing microbicide acceptability: a comprehensive and integrated approach. AIDS Behav. 12(2), 272–283 (2008).
  MedlineGoogle Scholar
• 35 Exner TM, Correale J, Carballo–Diéguez A et al. Women's anal sex practices: implications for formulation and promotion of a rectal microbicide. AIDS Education and Prevention 20(2), 148–159 (2008).
  Medline CASGoogle Scholar
• 36 Mcgowan I, Dezzutti C. Rectal microbicide development. Curr. Top. Microbiol. Immunol. 383, 117–136 (2014). •• A discussion on the need and current development of rectal microbicides to prevent HIV infection in the growing ‘men who have sex with men’ community.
  MedlineGoogle Scholar
• 37 Gorbach PM, Weiss RE, Fuchs E et al. The slippery slope: lubricant use and rectal sexually transmitted infections: a newly identified risk. Sex. Transm. Dis. 39(1), 59–64 (2012).
  MedlineGoogle Scholar
• 38 Mcgowan I. Rectal microbicides: can we make them and will people use them? AIDS Behav. 15(0), 66–71 (2011).
  Google Scholar
• 39 Abd-El-Maeboud KH, El-Naggar T, El-Hawi EMM, Mahmoud SaR, Abd-El-Hay S. Rectal suppository: commonsense and mode of insertion. Lancet 338(8770), 798–800 (1999).
  Google Scholar
• 40 Bradshaw A, Price L. Rectal suppository insertion: the reliability of the evidence as a basis for nursing practice. J. Clin. Nurs. 16(1), 98–103 (2007).
  MedlineGoogle Scholar
• 41 Saleem MA, Taher M, Sanaullah S et al. Formulation and evaluation of tramadol hydrochloride rectal suppositories. Indian. J. Pharm. Sci. 70(5), 640–644 (2008).
  Medline CASGoogle Scholar
• 42 Wada K, Uehara S, Ishii A et al. A Phase II clinical trial evaluating the preventive effectiveness of lactobacillus vaginal suppositories in patients with recurrent cystitis. Acta. Med. Okayama 70(4), 299–302 (2016).
  MedlineGoogle Scholar
• 43 Naz S, Memon NY, Sattar A, Baloch R. Diclofenac rectal suppository: an effective modality for perineal pain. J. Pak. Med. Assoc. 66(8), 1005–1008 (2016).
  MedlineGoogle Scholar
• 44 Ye X, Yin H, Lu Y, Zhang H, Wang H. Evaluation of hydrogel suppositories for delivery of 5-aminolevulinic acid and hematoporphyrin monomethyl ether to rectal tumors. Molecules 21(10), (2016).
  Google Scholar
• 45 Verdenelli MC, Cecchini C, Coman MM et al. Impact of probiotic SYNBIO^® administered by vaginal suppositories in promoting vaginal health of apparently healthy women. Curr. Microbiol. 73(4), 483–490 (2016).
  Medline CASGoogle Scholar
• 46 Lowry M. Rectal drug administration in adults: how, when, why. Nurs. Times. 112(8), 12–14 (2016).
  Google Scholar
• 47 Li B, Zaveri T, Ziegler GR, Hayes JE. Shape of vaginal suppositories affects willingness-to-try and preference. Antiviral. Res. 97(3), 280–284 (2013). •• A study into determining the willingness to try a vaginal suppository in relation to the shape and size of the suppository.
  Medline CASGoogle Scholar
• 48 Morrow KM, Hendrix C. Clinical evaluation of microbicide formulations. Antiviral Res. 88, Supplement(0), S40–S46 (2010).
  Medline CASGoogle Scholar
• 49 Morrow K, Rosen R, Richter L et al. The acceptability of an investigational vaginal microbicide, PRO 2000 gel, among women in a Phase I clinical trial. J. Women's Health 12(7), 655–666 (2003).
  MedlineGoogle Scholar
• 50 Whitehead SJ, Kilmarx PH, Blanchard K et al. Acceptability of Carraguard vaginal gel use among Thai couples. AIDS 20(17), 2141–2148 (2006).
  MedlineGoogle Scholar
• 51 Mahan ED, Morrow KM, Hayes JE. Quantitative perceptual differences among over-the-counter vaginal products using a standardized methodology: implications for microbicide development. Contraception 84(2), 184–193 (2011).
  MedlineGoogle Scholar
• 52 Moreton RC. Suppository Bases, Hard Fat. Pharmaceutical Press, PA, USA, 945–950 (2012).
  Google Scholar
• 53 Brown JM, Hess KL, Brown S, Murphy C, Waldman AL, Hezareh M. Intravaginal practices and risk of bacterial vaginosis and candidiasis infection among a cohort of women in the United States. Obstet. Gynecol. 121(4), 773–780 (2013).
  MedlineGoogle Scholar
• 54 Porter TL, Stewart R, Reed J, Morton K. Models of hydrogel swelling with applications to hydration sensing. Sensors (Basel, Switzerland) 7(9), 1980–1991 (2007).
  Medline CASGoogle Scholar
• 55 Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22(1), 11–23 (2005).
  Medline CASGoogle Scholar
• 56 Lane T, Pettifor A, Pascoe S, Fiamma A, Rees H. Heterosexual anal intercourse increases risk of HIV infection amoung young South African men. AIDS 20(1), 123–125 (2006).
  MedlineGoogle Scholar
• 57 Buckheit RW Jr, Roberson JL, Lackman-Smith C, Wyatt JR, Vickers TA, Ecker DJ. Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320). AIDS Res. Hum. Retroviruses 10(11), 1497–1506 (1994).
  Medline CASGoogle Scholar
• 58 Buckheit R Jr, Watson K, Morrow K, Ham A. Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res. 85, 142–158 (2010).
  Medline CASGoogle Scholar
• 59 Zaveri T, Hayes JE, Ziegler GR. Release of tenofovir from carrageenan-based vaginal suppositories. Pharmaceutics 6(3), 366–377 (2014).
  Medline CASGoogle Scholar
• 60 Zhang G, Zhang H, Yu H, Zhao Z, Yang J, Zhang M. Hypothetical rectal microbicide acceptability and factors influencing it among men who have sex with men in Tianjin, China. PLoS ONE 11(5), e0156561 (2016).
  MedlineGoogle Scholar
• 61 Jones DL, Weiss SM, Chitalu N, Bwalya V, Villar O. Acceptability of microbicidal surrogates among Zambian women. J. Sex. Transm. Dis. 35(2), 147–153 (2008).
  Google Scholar
• 62 Cranston RD, Lama JR, Richardson BA et al. MTN-017: a rectal Phase 2 extended safety and acceptability study of tenofovir reduced-glycerin 1% gel. Clin. Infect. Dis. 64(5), 614–620 (2017).
  Medline CASGoogle Scholar
• 63 Zaveri T, Primrose RJ, Surapaneni L, Ziegler GR, Hayes JE. Firmness perception influences women's preferences for vaginal suppositories. Pharmaceutics 6(3), 512–529 (2014).
  MedlineGoogle Scholar
• 64 Ham AS, Nugent ST, Beveridge E et al. Designing the suppository: a rational formulation design for rectal and vaginal administration. Presented at: HIV R4P. Chicago, IL, USA, October 17–21, 2016.
  Google Scholar
• 65 Holt BY, Morwitz VG, Ngo L et al. Microbicide preference among young women in California. J. Women's Health 15(3), 281–294 (2006).
  MedlineGoogle Scholar
• 66 Malonza IM, Mirembe F, Nakabiito C et al. Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel. AIDS (London, England) 19(18), 2157–2163 (2005).
  Medline CASGoogle Scholar
• 67 Schwartz JL, Mauck C, Lai JJ et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception 74(2), 133–140 (2006).
  Medline CASGoogle Scholar
• 68 Cao YJ, Caffo BS, Fuchs EJ et al. Quantification of the spatial distribution of rectally applied surrogates for microbicide and semen in colon with SPECT and magnetic resonance imaging. Br. J. Clin. Pharmacol. 74(6), 1013–1022 (2012).
  Medline CASGoogle Scholar
• 69 Hendrix CW, Fuchs EJ, Macura KJ et al. Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates. Clin. Pharmacol. Ther. 83(1), 97–105 (2008).
  Medline CASGoogle Scholar
• 70 Yahagi R, Machida Y, Onishi H. Mucoadhesive suppositories of ramosetron hydrochloride utilizing Carbopol. Int. J. Pharm. 193(2), 205–212 (2000).
  Medline CASGoogle Scholar
• 71 Yahagi R, Onishi H, Machida Y. Preparation and evaluation of double-phased mucoadhesive suppositories of lidocaine utilizing Carbopol and white beeswax. J. Control. Rel. 61(1–2), 1–8 (1999).
  Medline CASGoogle Scholar
• 72 Kawashima S, Inoue Y, Shimeno T, Fujiwara H. Studies on sustained-release suppositories. III. Rectal absorption of morphine in rabbits and prolongation of its absorption by alginic acid addition. Chem. Pharm. Bull. (Tokyo) 38(2), 498–505 (1990).
  Medline CASGoogle Scholar
• 73 Takatori T, Shimono N, Higaki K, Kimura T. Evaluation of sustained release suppositories prepared with fatty base including solid fats with high melting points. Int. J. Pharm. 278(2), 275–282 (2004).
  Medline CASGoogle Scholar
• 74 Carpenter CC, Cooper DA, Fischl MA et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 283(3), 381–390 (2000).
  Medline CASGoogle Scholar
• 75 Richman DD. HIV therapeutics. Science 272(5270), 1886–1888 (1996).
  Medline CASGoogle Scholar
• 76 Trabattoni D, Lo Caputo S, Biasin M et al. Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients. Clin. Diagn. Lab. Immunol. 9(5), 1114–1118 (2002).
  Medline CASGoogle Scholar